Bibliography
- COURTENAY-LUCK NS, EPENETOS AA, SIVOLAPENKO GB et al: Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet (1988) 2(8616)894–897.
- •Important early observations of idiotypic networks.
- GRANT S, KOSTAKOGLU L, KRIS M et al.: Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: a pilot trial. Eur. J. Nucl. Med. (1996) 23(2):145–149.
- FROST J, HANK J, REAMAN G et al.: A Phase I/IB trial of murine monoclonal anti-GD2 antibody14.G2a plus interleukin-2 in children with refractory neuroblas-toma: a report of the Children's Cancer Group. Cancer (1997) 80(2):317–333.
- ZHANG H, ZHANG S, CHEUNG N, RAGUPATHI G, LIVING-STON P: Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res. (1998) 58(13):2844–2849.
- LIVINGSTON P: Ganglioside vaccines with emphasis on GM2. Semin. Oncol (1998) 2 5 (6):636–645.
- •A sound review by a man with extensive experience in this field.
- LIVINGSTON P, WONG G, ADLURI S et al: Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. (1 9 9 4) 12 (5) :1036-1044.
- ••Ground-breaking; essential reading in conjunction with thispatent.
- RIETHMULLER G, SCHNEIDER-GADICKE E, SCHLIMOK G et al.: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet (1994) 343(8907):1177–1183.
- •This paper single-handedly breathed new life into the world of monoclonal antibodies.
- COBLEIGH M, VOGEL C, TRIPATHY D et al.: Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 222 women with HERZ overexpres-sion who relapsed following chemotherapy for metastatic breast cancer. In: Proc. ASCO. 1998, Los Angeles.
- VUIST WM, LEVY R, MALONEY DG: Lymphoma regres-sion induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expres-sion of high levels of bc1-2 protein. Blood (1994) 83 (4):899–906.
- •Is Ron Levy a future Nobel Prize-winner? Only if there's any justice in the world.
- HAWKINS R, ZHU D, OVECKA M et al.: Idiotypic vaccina-tion against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood (1994) 83(1 1) :3279–3288.
- BAUM RP, NIESEN A, HERTEL A et al.: Activating anti-idiotypic human antimouse antibodies for immunotherapy of ovarian carcinoma. Cancer (1994) 73 (3Supp0:1121–1125.
- DURRANT LG, BUCKLEY TJ, DENTON GW et al.: Enhanced cell-mediated tumor killing in patients immunized with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res. (1994) 54 (18) 4837–4840.
- FOON K, SEN G, HUTCHINS L et al.: Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin. Cancer Res. (1998) 4(5):1117–1124.
- MITTELMAN A, CHEN Z, LIU C, HIRAI S, FERRONE S:Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-High Molecular Weight Associated Antigen immunity in three patients with advanced malignant melanoma immunized with mouse anti-idiotypic monoclonal antibody MK2-23. Cancer Res. (1994) 54:415–421.
- NICHOLSON S, GALLOP J, LAW P, THOMAS H, GEORGE A:Monitoring antibody responses to cancer vaccination with a resonant mirror biosensor. Lancet (1999) 3 5 3: 808.
- •A new way of looking at responses to cancer vaccines.